Spanish Breast Cancer Research Group clinical trial pipeline

3 trials changed in the last 30 days: 1 stopped, 2 with notable changes, 0 with minor changes only.

1. Stopped

   ALPHABET · Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab…ALPHABET · Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)

   Trial terminated

   Also in this update: Primary completion date changed from estimate of Jun 2026 to Dec 23, 2025

   Spanish Breast Cancer Research Group·Phase 3· NCT05063786· Registry history of NCT05063786 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

2. Notable

   REGISTEM · Registry Study · Unresectable Locally Advanced or…REGISTEM · Registry Study · Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)

   Primary and study completion pushed from Jun 2026 to Jun 2032

   Spanish Breast Cancer Research Group·Not specified· NCT02819882· Registry history of NCT02819882 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

3. Notable

   neoAGORA · Utility of Serial Liquid Biopsy (ctDNA) · Early-Stage…neoAGORA · Utility of Serial Liquid Biopsy (ctDNA) · Early-Stage Breast Cancer

   Recruitment opened

   Spanish Breast Cancer Research Group·Not specified· NCT07718841· Registry history of NCT07718841 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.